These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 10772372)
21. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687 [TBL] [Abstract][Full Text] [Related]
22. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease. Kuo PT; Wilson AC; Kostis JB; Moreyra AE Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177 [TBL] [Abstract][Full Text] [Related]
23. Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. Ramires JA; Mansur AP; Solimene MC; Maranhão R; Chamone D; da Luz P; Pileggi F Int J Cardiol; 1995 Feb; 48(2):115-20. PubMed ID: 7774989 [TBL] [Abstract][Full Text] [Related]
25. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197 [TBL] [Abstract][Full Text] [Related]
26. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. Ojala JP; Helve E; Karjalainen K; Tarkkanen A; Tikkanen MJ Atherosclerosis; 1990 May; 82(1-2):85-95. PubMed ID: 2360923 [TBL] [Abstract][Full Text] [Related]
27. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. Senaratne MP; Griffiths J; Mooney D; Kasza L; Macdonald K; Hare S Am Heart J; 2001 Dec; 142(6):975-81. PubMed ID: 11717600 [TBL] [Abstract][Full Text] [Related]
29. [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study]. González-Juanatey JR; Cordero A; Vitale GC; González-Timón B; Mazón P; Bertomeu V Rev Esp Cardiol; 2011 Oct; 64(10):862-8. PubMed ID: 21835533 [TBL] [Abstract][Full Text] [Related]
31. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695 [TBL] [Abstract][Full Text] [Related]
32. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Lal SM; Hewett JE; Petroski GF; Van Stone JC; Ross G Am J Kidney Dis; 1995 Apr; 25(4):616-22. PubMed ID: 7702060 [TBL] [Abstract][Full Text] [Related]
33. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR; Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795 [TBL] [Abstract][Full Text] [Related]
34. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Koren-Morag N; Tanne D; Graff E; Goldbourt U Arch Intern Med; 2002 May; 162(9):993-9. PubMed ID: 11996608 [TBL] [Abstract][Full Text] [Related]
35. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509 [TBL] [Abstract][Full Text] [Related]
36. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Gaw A; Packard CJ; Lindsay GM; Murray EF; Griffin BA; Caslake MJ; Colquhoun I; Wheatley DJ; Lorimer AR; Shepherd J Arterioscler Thromb Vasc Biol; 1996 Feb; 16(2):236-49. PubMed ID: 8620338 [TBL] [Abstract][Full Text] [Related]
37. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. Schiel R; Bambauer R; Müller UA Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646 [TBL] [Abstract][Full Text] [Related]
38. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin. Rose HG; Haft GK; Juliano J Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325 [TBL] [Abstract][Full Text] [Related]
39. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815 [TBL] [Abstract][Full Text] [Related]
40. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Ali F; Laurin MY; Larivière C; Tremblay D; Cloutier D Can J Clin Pharmacol; 2003; 10(3):101-6. PubMed ID: 14506507 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]